RUNX3 Inhibits the Invasion and Metastasis of Human Colon Cancer HT‐29 Cells by Upregulating MMP‐2/9

Abstract

Objective. To investigate the effect of Runt-associated transcription factor 3 (RUNX3) on the invasion and metastasis of human colon cancer HT-29 cells and to preliminarily explore the mechanism of its anticancer effect. Methods. e RUNX3 plasmid vector was transfected into human colon cancer HT-29 cells by liposome-mediated transfection, while the empty vector and the blank group were used as the control group. After Geneticin (G418) screening, HT-29 cells with stable expression of RUNX3 gene were obtained. e expressions of mRNA and proteins of RUNX3 and metalloproteinases (MMP)-2/9 were detected by reverse transcription-polymerase chain reaction (RT-PCR) and western blot. Cell proliferation was determined by MTT assay. e effect of RUNX3 on invasion and metastasis of HT-29 cells was evaluated by scratch injury assay, Transwell chamber, and Matrigel invasion model. Results. RUNX3 was expressed stably in HT-29 cells after transfection. e expressions of RUNX3 mRNA and proteins in the experimental group were significantly higher than those in the blank/empty vector groups. Meanwhile, the expressions of MMP-2/9 mRNA and proteins in the observation group were significantly lower than those in the blank group and the empty vector group. e proliferation and migration ability in the experimental group was significantly lower than blank/ empty vector groups from the third day. Transwell chamber experiment and Matrigel invasion assay showed that the number of Transwell cells was decreased significantly than blank/empty vector groups, but no difference was found between the blank group and the empty vector group. Conclusion. RUNX3 can inhibit the invasion and metastasis of human colon cancer HT-29 cells, and the mechanism may be related to decreased expression of MMP-2 and MMP-9.

Coelomic Fluid of Eisenia fetida Ameliorates Cetuximab to Reduce K‐Ras and Vimentin Expression through Promoting RUNX3 in an AOM/DSS‐Induced Colitis Associated Colon Cancer

“…RUNX3 is important proteins involved in cell cycle regulation [ 26 ]. Therefore, we wanted to determine if CFEF-cetuximab treatments influenced the abundance of RUNX3 in cancer cells.…”

“…Coelomic fluid has been known to be used as a therapy for several diseases because it has anti-inflammatory, antioxidant, antibacterial, and antitumor effects [7]. Biological substances contained coelomic fluid including lectin [8] and earthworm fibrinolytic enzyme also known as lumbrokinase [26,29,30]. Lectins have been proven to be used as anticancer in the MCF-7 cell line via the MAPK pathway by targeting EGFR to induce cell apoptosis [25].…”

“…The expression of protein RUNX3 was found to be substantially associated with decreased survival of CRC patients [ 25 , 27 , 28 , 32 ]. RUNX3 overexpression is associated with decreased breast cancer cell invasiveness [ 26 – 29 , 32 ]. The overexpressing RUNX3 cells had reduced invasive potential of the cells.…”

“…When the combination of CFEF and cetuximab was applied, both expressions of β-catenin and E-cadherin were higher than cetuximab or CFEF alone (P < 0.05). [26].…”

“…e improving of vimentin can occur through pathways involving β-catenin and TGF-β. β-Catenin increases EMT through activation of the vimentin signal pathway [25][26][27][28]32]. Epithelial mesenchymal transformation during development and oncogenesis is an essential biological Evidence-Based Complementary and Alternative Medicine process.…”